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CLINICAL RESEARCH
Coronary heart disease
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Aims In the TRITON-TIMI 38 trial, greaterplateletinhibition with prasugrelreduced the ﬁrstoccurrence of the primaryend-
point (cardiovascular death, MI, or stroke) compared with clopidogrel in patients with an acute coronary syndrome
(ACS) undergoing planned percutaneous coronary intervention. We hypothesized that prasugrel would reduce not
only ﬁrst events but also recurrent primary endpoint events and therefore total events compared with clopidogrel.
Methods
and results
Poisson regression analysis was performed to compare the number of occurrences of the primary endpoint between
prasugrel and clopidogrel in TRITON-TIMI 38. Landmark analytic methods were used to evaluate the risk of a recur-
rent primary endpoint event following an initial non-fatal endpoint event. Among patients with an initial non-fatal
event, second events were signiﬁcantly reduced with prasugrel compared to clopidogrel (10.8 vs. 15.4%, HR 0.65,
95% CI 0.46–0.92; P ¼ 0.016), as was CV death following the non-fatal event (3.7 vs. 7.1%, HR 0.46, 95% CI
0.25–0.82; P ¼ 0.008). Overall there was a reduction of 195 total primary efﬁcacy events with prasugrel vs. clopido-
grel (rate ratio 0.79, 95% CI 0.71–0.87; P , 0.001). Recurrent bleeding events occurred infrequently (TIMI major
non-CABG bleeds: four with prasugrel and two with clopidogrel). Study drug discontinuation was frequent following
the initial major bleeding event (42% of patients discontinued study drug).
Conclusion While standard statistical analytic techniques for clinical trials censor patients who experience a component of the primary
composite endpoint, total cardiovascular events remain important to both patients and clinicians. Prasugrel, a more potent
anti-plateletagent,reducedbothﬁrstandsubsequentcardiovasculareventscomparedwithclopidogrelinpatientswithACS.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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Introduction
In standard statistical analysis of clinical outcomes trial data using
survival methodology, patients who experience a component of
a primary composite endpoint are censored from the analysis
following the initial event. Such patients continue to be followed
during the trial and are at risk for the occurrence of additional
events, but second and third order events are generally not con-
sidered in a primary endpoint efﬁcacy analysis. However, in a real-
world clinical setting, both patients and clinicians are concerned
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subsequent events as well. Additionally, patients who experience
multiple events may be a subset of subjects who are poor respon-
ders to therapy. Identiﬁcation of baseline characteristics, including
platelet response measures in the setting of an acute coronary syn-
drome, among such subjects may allow modiﬁcations of the clinical
management strategy prior to the occurrence of subsequent
events, such as providing more intensive or additional therapy.
As previously reported,
1 The TRial to Assess Improvement in
Therapeutic Outcomes by Optimizing Platelet InhibitioN with Pra-
sugrel (TRITON)-TIMI 38 showed an overall reduction in the com-
posite endpoint of death from cardiovascular causes, non-fatal MI,
or non-fatal stroke over a median duration of therapy of 14.5
months (interquartile range 8.8 months, 15.1 months) with inten-
sive dual antiplatelet therapy with prasugrel compared to the
approved regimen of clopidogrel in patients with ACS undergoing
percutaneous coronary intervention (PCI). These beneﬁts of pra-
sugrel over clopidogrel in preventing events were achieved at
the cost of an increased rate of TIMI major non-CABG-related
bleeding.
1 We hypothesized that not only ﬁrst events but sub-
sequent events would also be reduced with greater platelet inhi-
bition using prasugrel when compared with standard therapy
with clopidogrel. We also sought to evaluate whether repeated
bleeding events occurred more frequently with prasugrel.
Methods
The study design and primary results of the TRITON-TIMI 38 trial have
been published previously.
1,2 A total of 13 608 patients with an acute
coronary syndrome (both UA/NSTEMI and STEMI) for whom a PCI
was planned were enrolled in TRITON-TIMI 38 and were randomized
to prasugrel (loading dose of 60 mg and daily maintenance dose of
10 mg) or the approved regimen of clopidogrel (300 mg loading dose
and 75 mg daily maintenance dose).
1 Randomization was to occur prior
to the onset of PCI and blinded study drug administration was to be
administered as soon as possible after randomization. During the main-
tenance phase, patients were to receive blinded study drug and aspirin
(suggested dose of 75–162 mg). After hospital discharge, follow-up
visits were conducted at 30 days, 90 days, and at 3 month intervalsthere-
after for a minimum of 6 months and maximum of 15 months.
All endpoints used in the analyses in the initial
1 as well as this report
were adjudicated by members of an independent clinical events com-
mittee who were blinded to the treatment assignment.
2 Fatal events
were counted as a single event, not as two separate events. For
example, if a patient experienced an MI and then had cardiovascular
death with the cause of death adjudicated as due to the MI, the event
was considered one fatal MI event and was not counted as both an MI
and cardiovascular death. Patients were to remain on study drug even
if the subject experienced one of the efﬁcacy endpoints of the study.
If a subjectexperienceda bleeding event, study drug could becontinued
or discontinued at the treating physician’s discretion.
Efﬁcacy comparisons were performed according to the intention-
to-treat principle. A sensitivity analysis was performed that included only
efﬁcacy events that occurred during the ‘at-risk’ period, deﬁned as on
study drug or within 7 days after permanent study drug discontinuation.
The analysis of bleeding events was also restricted to the ‘at-risk’ period.
Baseline clinical characteristics are presented as frequencies for cat-
egorical variables and medians and interquartile ranges for continuous
variables. Comparisons between baseline characteristics for patients
with no events, a single event, or multiple events (Table 1), as well
as for the comparison of prasugrel with clopidogrel in the cohort of
...............................................................................................................................................................................
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Table 1 Baseline characteristics in patients with no events, single event, or multiple events
No events (n 5 12 184) Single event (n 5 1284) Multiple events (n 5 140) P-value
Age  75 years 1511 (12.4%) 256 (19.9%) 42 (30.0%) ,0.001
Age (years) 60 (52, 69) 63 (55, 72) 69 (60, 78) ,0.001
Gender (male) 9054 (74.3%) 939 (73.1%) 92 (65.7%) 0.05
White race 11236 (92.6%) 1174 (91.6%) 127 (90.7%) 0.29
History of hypertension 7735 (63.5%) 893 (69.5%) 113 (80.7%) ,0.001
History of hypercholesterolaemia 6778 (55.6%) 721 (56.2%) 81 (57.9%) 0.82
History of diabetes 2718 (22.3%) 371 (28.9%) 57 (40.7%) ,0.001
Current tobacco use 4706 (38.6%) 462 (36.0%) 27 (19.3%) ,0.001
Prior MI 2072 (17.0%) 308 (24.0%) 54 (38.6%) ,0.001
Prior CABG 862 (7.1%) 145 (11.3%) 31 (22.1%) ,0.001
Creatinine clearance (mL/min) 100.2 (77.8, 126.8) 92.5 (69.4, 120.6) 74.0 (55.5, 101.5) ,0.001
CrCl ,60 mL/min 1260 (10.5%) 186 (15.0%) 44 (32.1%) ,0.001
Stent used for index PCI 11517 (94.5%) 1195 (93.1%) 132 (94.3%) 0.10
BMS used for index PCI 5772 (47.4%) 619 (48.2%) 70 (50.0%) 0.71
DES used for index PCI 5745 (47.2%) 576 (44.9%) 62 (44.3%) 0.24
Multivessel PCI 1670 (14.0%) 195 (15.6%) 31 (22.8%) 0.006
NSTEMI/UA 9040 (74.2%) 934 (72.7%) 100 (71.4%) 0.41
Randomization ,0.001
Prasugrel 6170 (50.6%) 595 (46.3%) 48 (34.3%)
Clopidogrel 6014 (49.4%) 689 (53.7%) 92 (65.7%)
S.A. Murphy et al. 2474patients with at least one non-fatal event (Table 2), were made using x
2
test for categorical variables and Wilcoxon rank for continuous vari-
ables. Poisson regression analysis was performed to compare the
total number of occurrences of the primary endpoint between all
patients in the prasugrel and clopidogrel groups. Poisson regression
is a generalized linear model applied when analysing multiple discrete
counts (i.e. number of occurrences of an event) over a period of
time (i.e. duration of follow-up in the trial). Landmark analytic
methods were used to evaluate the risk of a second event following
the initial event, with entry time into the analysis being set at the
time of the ﬁrst event. The landmark method of survival analysis uti-
lizes a ﬁxed timepoint from which patients were entered into the
analysis and considered at risk (in this case, after the occurrence of
an initial primary endpoint event) to assess the subsequent response
in the treatment groups. Landmark event rates were presented as
Kaplan–Meier failure estimates and were compared using the log
rank test. Hazard ratios for the landmark analyses were calculated
using Cox proportional hazard models. All tests were two-sided
with a P-value ,0.05 considered to be signiﬁcant. Due to the explora-
tory nature of the analysis, no adjustments were made to thresholds
for signiﬁcance for multiple testing. Analyses were performed using
Stata/SE 9.2 (Stata Corp., College Station, TX, USA).
Results
Among patients with no events, the median length of follow-up
was 14.8 months (25th/75th percentile, 11.5 and 15.2 months
overall; same for both prasugrel and clopidogrel); among patients
experiencing at least one event, the median length of follow-up
was 14.3 months (25th/75th percentile 7.0 and 15.1 months).
Patients with multiple events were older, had more comorbidities
at study entry including hypertension and diabetes, and tended
more frequently to be females (Table 1). Baseline characteristics
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Table 2 Baseline characteristics for prasugrel vs. clopidogrel among patients with at least one non-fatal event
Prasugrel (n 5 529) Clopidogrel (n 5 674) P-value
Age  75 years 107 (20.2%) 117 (17.4%) 0.20
Age (years) 63 (55, 72) 62 (54, 71) 0.06
Gender (male) 387 (73.2%) 496 (73.6%) 0.87
White race 486 (91.9%) 623 (92.7%) 0.59
Region 0.80
North America 171 (32.3%) 227 (33.7%)
South America 23 (4.3%) 36 (5.3%)
Western Europe 141 (26.7%) 163 (24.2%)
Eastern Europe 117 (22.1%) 145 (21.5%)
Rest of World 77 (14.6%) 103 (15.3%)
History hypertension 382 (72.2%) 471 (69.9%) 0.38
History hypercholesterolaemia 296 (56.0%) 398 (59.1%) 0.28
History of diabetes 137 (25.9%) 210 (31.2%) 0.05
Current tobacco use 184 (34.8%) 242 (35.9%) 0.69
Prior MI 126 (23.8%) 177 (26.3%) 0.33
Prior CABG 67 (12.7%) 82 (12.2%) 0.79
Creatinine clearance (mL/min) 92.2 (69.9, 118.4) 94.6 (70.7, 125.8) 0.13
CrCl ,60 mL/min 77 (14.7%) 99 (14.9%) 0.95
PCI performed 525 (99.2%) 669 (99.3%) 0.98
CABG performed during index hospitalization 7 (1.3%) 16 (2.4%) 0.19
Stent used for index PCI 498 (94.1%) 633 (93.9%) 0.87
BMS used for index PCI 252 (47.6%) 319 (47.3%) 0.92
DES used for index PCI 246 (46.5%) 314 (46.6%) 0.98
Anti-thrombin 0.27
UFH 353 (68.5%) 413 (63.1%)
LMWH 38 (7.4%) 59 (9.0%)
Bivalirudin 15 (2.9%) 23 (3.5%)
Other/combo 109 (21.2%) 160 (24.4%)
GP2b3a inhibitor used during index hospitalization 302 (57.1%) 401 (59.5%) 0.40
SBP (mm Hg) 132 (120, 150) 135 (120, 151) 0.31
Heart rate (b.p.m.) 71 (62, 80) 71 (62, 80) 0.76
NSTEMI/UA 390 (73.7%) 503 (74.6%) 0.72
MV PCI 94 (18.2%) 92 (13.9%) 0.04
Recurrent events with prasugrel vs. clopidogrel 2475among patients experiencing at least one non-fatal event compar-
ing those randomized to prasugrel vs. clopidogrel are shown in
Table 2. While most baseline characteristics were similar
between the prasugrel and clopidogrel groups, those randomized
to prasugrel were slightly older, less likely to have a history of dia-
betes, and more likely to have undergone multivessel PCI (Table 2).
Efﬁcacy
As previously reported,
1 the primary endpoint of ﬁrst occurrence
of CV death, MI, or stroke was signiﬁcantly reduced in the prasu-
grel group when compared with the clopidogrel group (9.9%,
n ¼ 643 vs. 12.1%, n ¼ 781, HR 0.81, 95% CI 0.73–0.90;
P , 0.001). In addition to the reduction in ﬁrst events, subsequent
events were also reduced in the prasugrel group (n ¼ 58 in the
prasugrel group vs. n ¼ 115 in the clopidogrel group, P , 0.001,
Figure 1), resulting in 195 fewer total primary events during
follow-up (total events n ¼ 701 vs. n ¼ 896, rate ratio 0.79,
95% CI 0.71–0.87; P , 0.001). Results were consistent when
using all-cause mortality instead of CV death in the composite end-
point, with signiﬁcantly fewer total events with prasugrel compared
with clopidogrel (n ¼ 750 with prasugrel vs. n ¼ 937 with clopido-
grel, rate ratio 0.80, 95% CI 0.73–0.89; P , 0.001). In a sensitivity
analysis that included only primary endpoint events that occurred
while on study drug or within 7 days after the study drug was dis-
continued, prasugrel was associated with a reduction in ﬁrst events
(9.7% in the prasugrel group vs. 11.4% in the clopidogrel group, HR
0.84, 95% CI 0.76–0.94; P ¼ 0.002), subsequent events (n ¼ 51 vs.
n ¼ 98, P , 0.001), and total events (rate ratio 0.81, 95% CI 0.73–
0.90, n ¼ 657 vs. n ¼ 811; P , 0.001).
In a landmark analysis from the time of the ﬁrst event to
recurrent event or last follow-up, a second primary endpoint
event occurred in 10.8% of the prasugrel group and 15.4% of
the clopidogrel group (HR 0.65, 95% CI 0.46–0.92; P ¼ 0.016)
(Figure 2A). After adjusting for covariates that were associated
with the occurrence of an additional event (age, gender, history
of hypertension, history of diabetes, non-use of tobacco products,
prior MI, creatinine clearance ,60 mL/min, and multivessel PCI),
the adjusted HR is 0.66 (95% CI 0.46–0.95; P ¼ 0.024). Cardiovas-
cular death following a non-fatal MI or stroke was also signiﬁcantly
reduced in the prasugrel group compared with the clopidogrel
group (3.7 vs. 7.1%, HR 0.46, 95% CI 0.25–0.82; P ¼ 0.008)
(Figure 2B). Results were similar when adjusting for multivessel
PCI, which was not balanced between treatment groups in this
cohort, as well as covariates that were associated with the occur-
rence of cardiovascular death following an initial non-fatal event
(age, history of hypercholesterolaemia, history of diabetes, non-
use of tobacco products, prior MI, and creatinine clearance
,60 mL/min) (HR 0.49, 95% CI 0.26–0.91; P ¼ 0.023).
The reduction in second events with prasugrel was consistent in
several key subgroups, including the elderly, gender, stent type,
index event, and creatinine clearance (Figure 3). A signiﬁcant inter-
action was observed between history of diabetes and treatment on
Figure 1 Additional primary endpoint events by randomized
therapy. The prasugrel group had a lower number of both ﬁrst
events (P , 0.001), additional events (P , 0.001), and total
events (P , 0.001).
Figure 2 (A) Landmark analysis of time from ﬁrst event to second event by randomized therapy. The occurrence of a subsequent ischaemic
event was signiﬁcantly reduced in the prasugrel group (HR 0.65, 95% CI 0.46–0.92; P ¼ 0.016). (B) Landmark analysis of time from ﬁrst event to
cardiovascular death by randomized therapy. Cardiovascular mortality following a non-fatal ischaemic event occurred signiﬁcantly less fre-
quently among patients treated with prasugrel (HR 0.46, 95% CI 0.25–0.82).
S.A. Murphy et al. 2476the risk of a second event (Pinteraction ¼ 0.036), with a large risk
reduction in subsequent events in diabetics treated with prasugrel
(HR 0.40, 95% CI 0.21–0.75, P ¼ 0.003).
Bleeding
Initial TIMI major non-CABG bleeding events were more frequent
in the prasugrel group (2.4 vs. 1.8%, HR 1.32, 95% CI 1.03–1.68,
P ¼ 0.03),
1 as were TIMI minor non-CABG bleeding events (2.7
vs. 2.0%, HR 1.31, 95% CI 1.04–1.66; P ¼ 0.02). Recurrent bleeding
events during the at-risk period occurred infrequently in both
arms, due to a high rate of study drug discontinuation following
the initial bleeding event (overall 42% of patients who had an
initial TIMI major non-CABG bleeding event discontinued study
drug; 42% for prasugrel vs. 43% for clopidogrel, P ¼ NS). The fre-
quency of such recurrent events was similar between the treat-
ment arms, with four repeat TIMI major non-CABG bleeds in
the prasugrel group and two in the clopidogrel group. There
were ﬁve repeat TIMI minor non-CABG bleeds in each treatment
group. Likewise, among patients with at least one TIMI non-CABG
major or minor bleed, there were 17 recurrent non-CABG TIMI
major or minor bleeding events in the prasugrel group and 13 in
the clopidogrel group.
Of the 26 patients with a TIMI non-CABG fatal bleed, three
patients in the prasugrel group had experienced an adjudicated
bleeding event by TIMI criteria prior to the fatal bleed, one of
which was a TIMI non-CABG major bleed 4 months prior to the
fatal bleed and two of which were TIMI non-CABG minor
bleeds, one 2 days prior to the fatal bleed, and one 4 days prior
to the fatal bleed. None of the patients with a TIMI non-CABG
fatal bleed in the clopidogrel group had experienced a prior TIMI
major or minor bleeding event.
Discussion
This analysis from the TRITON-TIMI 38 trial demonstrates that
randomization to prasugrel, a drug that results in greater platelet
inhibition when compared with clopidogrel, prevented not only
the ﬁrst primary endpoint event but also reduced subsequent and
therefore the total number of primary endpoint events among
patientswithanACSundergoingPCI.Whiletheearlybeneﬁtofpra-
sugrel was evident in the primary analysis in the report of the main
results as shown by the immediate separation of the Kaplan–Meier
curves,
1 our ﬁndings suggest that continued therapy with a regimen
that provides higher levels of IPA remains important, even after an
ischaemic event has occurred. Indeed, intensive anti-platelet
therapy seems to be of added beneﬁt to those who have already
hadsuchanevent,anobservationevidentinboththeintent-to-treat
and on-treatment analyses.
Despite the practice of censoring patients who experience a
component of the primary composite endpoint in standard
Figure 3 Subsequent primary events during follow-up by randomized therapy among subgroups. Among patients with a ﬁrst, non-fatal ischae-
mic event, second events were directionally lower with prasugrel in all subgroups (i.e. point estimate falls to the left of the line of unity). With
the exception of history of diabetes (interaction P ¼ 0.036), there were no other signiﬁcant interactions by subgroup. Rates are Kaplan–Meier
failure rates at 15 months.
Recurrent events with prasugrel vs. clopidogrel 2477statistical analysis of clinical outcomes trial data when applying sur-
vival methods, what is of importance to patients and from a health-
care resource utilization perspective are the outcomes for a
patient during the course of the entire trial.
3 Multiple events
experienced by a given patient require more hospitalizations,
tests, treatments, and physician visits, resulting in increased costs.
From a patient perspective, additional ischaemic events result in
a higher mortality as well as an impaired quality of life.
4
Several validated scoring systems accurately predict those at an
increased risk of events following an ACS based on baseline
characteristics and index presentation.
5–9 While risk scores were
higher and baseline clinical risk factors (e.g. older age, more fre-
quent diabetes, hypertension, and prior MI) were more frequent
among patients with multiple events than those with a single
event, other unidentiﬁed factors also inﬂuence the risk of recur-
rent ischaemic events. Based on the observation that total
events in this study were higher with clopidogrel, it is possible
that those patients with recurrent events may be more resistant
to anti-platelet therapy, and/or more likely to be hyporesponders
to platelet inhibition, a concept previously reported to be associ-
ated with an increased risk of thrombotic events.
10–14 Several
studies have shown that prasugrel produces higher and more con-
sistent levels of the active metabolite that binds to the platelet
P2Y12 receptor than clopidogrel, both at the approved dose
used in the current study as well as at higher doses.
15,16
Patients with diabetes experiencing ACS are of particular inte-
rest since they are known to have an increased rate of cardiovas-
cular events and more aggregable platelets
17–19 and the primary
analysis of TRITON-TIMI 38 showed that they responded particu-
larly well to prasugrel. In this analysis, we observed that a signiﬁ-
cant interaction occurred between diabetes and randomized
therapy on the risk of a recurrent primary endpoint event, with
a hazard ratio of 0.40 favouring prasugrel in patients with diabetes.
There was no difference between treatment groups in the risk of
recurrent bleeding events, although such events were rare due to a
high rate (42%) of study drug discontinuation following the initial
bleeding event. As per the protocol, if a subject experienced a
bleeding event during the trial, the investigator was permitted to
discontinue study drug therapy and restart study drug after the
bleeding event had subsided. However, a large number of patients
in both arms who experienced a major bleeding event permanently
discontinued study drug.
Limitations
It should be noted that with landmark analyses comparing two
therapies within a trial, the original randomization assigned at
study entry is subject to survivor bias and study drug discontinu-
ation. However, among patients with a non-fatal ischaemic event
who comprised the landmark analysis cohort, there were few sig-
niﬁcant differences in evaluated baseline characteristics between
the prasugrel and clopidogrel groups (age, history of diabetes,
and multivessel PCI). When the landmark analysis for a second
event was adjusted for these imbalanced covariates, as well as cov-
ariates associated with the occurrence of an additional event, pra-
sugrel remained associated with a lower risk of additional events
compared with clopidogrel (univariate HR 0.65; adjusted HR
0.66, P ¼ 0.024). Additionally, there was no difference in mortality
between treatment groups overall in the TRITON-TIMI 38 trial
(3.0 vs. 3.2%, HR 0.95, P ¼ 0.64). The impact that continued
therapy with prasugrel compared with clopidogrel could have
had on recurrent bleeding events may not be fully assessed due
to the high rate of study drug discontinuation (in both treatment
arms) following the initial bleeding event and the infrequent
nature of repeat bleeding events.
Clinical implications
Prasugrel, a more potent thienopyridine than clopidogrel, reduced
not only the ﬁrst but also subsequent occurrences of primary end-
point events compared with the approved dose of clopidogrel.
This observation emphasizes the need for continued high levels
of platelet inhibition following an acute coronary syndrome.
Patients who experience an ischaemic event despite treatment
with clopidogrel may be hyporesponders to this drug and may
require more intensive platelet P2Y12 inhibition to prevent the
occurrence of subsequent adverse thrombotic complications.
Patients at greatest risk for events, such as those who have
already experienced an event while on clopidogrel (especially dia-
betic patients) may experience especially salutary effects when
treated with a drug that provides more intensive inhibition of
the platelet P2Y12 receptor.
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